Development of a Ferritin-Based Nanoparticle Vaccine against Classical Swine Fever.
B-cell antigenic epitope
E2 protein
classical swine fever virus
ferritin nanoparticles
immune responses
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
22 Aug 2024
22 Aug 2024
Historique:
received:
30
06
2024
revised:
14
08
2024
accepted:
20
08
2024
medline:
31
8
2024
pubmed:
31
8
2024
entrez:
29
8
2024
Statut:
epublish
Résumé
The occurrence of classical swine fever (CSF) poses a significant threat to the global swine industry. Developing an effective and safe vaccine is crucial for preventing and controlling CSF. Here, we constructed self-assembled ferritin nanoparticles fused with the classical swine fever virus (CSFV) E2 protein and a derived B cell epitope (Fe-E2B) using a baculovirus expression system (BVES), demonstrating enhanced immunogenicity. Furthermore, we provide a detailed evaluation of the immunological efficacy of the FeE2B in rabbits. The results showed that robust and sustained antibody responses were detected in rabbits immunized with the Fe-E2B nanoparticle vaccine, comparable to those elicited by commercially available vaccines. Additionally, we demonstrated that the vaccine effectively activated crucial immune factors IFN-γ and IL-4 in vivo, increasing their levels by 1.41-fold and 1.39-fold, respectively. Immunization with Fe-E2B enabled rabbits to avoid viremia and stereotypic fever after CSFV challenge. In conclusion, this study highlights the potential of ferritin nanoparticles as antigen-presenting carriers to induce robust immune responses, proposing a candidate vaccine strategy for the prevention and control of CSF.
Identifiants
pubmed: 39204071
pii: vaccines12080948
doi: 10.3390/vaccines12080948
pmc: PMC11360710
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : National Natural Science Foundation of China under Grant
ID : 32172824 and 32102643
Organisme : Guangzhou Basic and Applied Basic Research Program
ID : 202201010489
Organisme : Guangzhou Science and Technology Program
ID : 202206010161
Organisme : Quality Improvement Project of South China Agricultural University
ID : C18
Organisme : South China Agricultural University and Wen's Group Science and Technology Innovation Centre Results in Incubation Project
ID : WS-HN-JKYZ-202404-118
Références
Viruses. 2017 Apr 21;9(4):
pubmed: 28430168
Virus Res. 2010 Sep;152(1-2):65-72
pubmed: 20558217
Viruses. 2021 Mar 10;13(3):
pubmed: 33801868
ACS Nano. 2021 Feb 23;15(2):2738-2752
pubmed: 33464829
Vaccine. 2018 Nov 19;36(48):7353-7360
pubmed: 30366801
Virology. 2003 Jun 20;311(1):96-104
pubmed: 12832207
J Control Release. 2019 Aug 10;307:166-185
pubmed: 31226356
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2023 Mar;15(2):e1857
pubmed: 36184873
Biomaterials. 2021 Jan;268:120597
pubmed: 33360074
Vaccines (Basel). 2022 Nov 17;10(11):
pubmed: 36423041
ACS Nano. 2022 Aug 23;16(8):11769-11780
pubmed: 35758934
Vet Res. 2023 Jul 11;54(1):57
pubmed: 37434231
Pharmaceutics. 2022 Nov 22;14(12):
pubmed: 36559049
Vet Microbiol. 2010 Apr 21;142(1-2):51-8
pubmed: 19896784
Expert Rev Vaccines. 2007 Aug;6(4):591-603
pubmed: 17669012
Vaccine. 2013 Jul 18;31(33):3327-32
pubmed: 23735678
Surgery. 2010 Sep;148(3):573-81
pubmed: 20227099
Virus Res. 2014 Apr;183:117-22
pubmed: 24553098
Vaccine. 2014 Jan 9;32(3):327-37
pubmed: 24295808
Vaccines (Basel). 2021 Jan 13;9(1):
pubmed: 33451123
J Virol Methods. 2006 Jun;134(1-2):125-9
pubmed: 16455143
Emerg Infect Dis. 2019 Jun;25(6):1228-1231
pubmed: 30870139
NPJ Vaccines. 2021 May 13;6(1):70
pubmed: 33986287
Nanomedicine (Lond). 2014 Jul;9(10):1545-64
pubmed: 25253501
Vaccine. 2014 Nov 20;32(49):6607-13
pubmed: 25446823
Adv Drug Deliv Rev. 2011 Sep 10;63(10-11):943-55
pubmed: 21679733
Virus Res. 2008 Aug;135(2):267-72
pubmed: 18485511
Virus Res. 2009 Jun;142(1-2):169-74
pubmed: 19428750
Viruses. 2017 Jul 05;9(7):
pubmed: 28678154
Vaccines (Basel). 2021 Feb 15;9(2):
pubmed: 33671909
Nanomedicine. 2006 Sep;2(3):137-49
pubmed: 17292136
Vet Microbiol. 2000 Apr 13;73(2-3):93-102
pubmed: 10785320
Virol J. 2011 Jul 30;8:378
pubmed: 21801433
Virus Res. 2014 Jan 22;179:1-11
pubmed: 24211665
Viruses. 2021 Apr 12;13(4):
pubmed: 33921513
Transbound Emerg Dis. 2018 May;65 Suppl 1:248-261
pubmed: 28795533
Virus Genes. 2019 Apr;55(2):238-242
pubmed: 30607768
Angew Chem Int Ed Engl. 2019 Jan 14;58(3):670-680
pubmed: 30016571
Arch Virol. 2011 Jun;156(6):1041-4
pubmed: 21340740
Virol J. 2021 Feb 24;18(1):44
pubmed: 33627167
Vaccine. 2011 Oct 26;29(46):8364-72
pubmed: 21888938
Virus Res. 2015 Feb 2;197:35-47
pubmed: 25510481
Emerg Infect Dis. 2018 Apr;24(4):798-800
pubmed: 29553332
Adv Healthc Mater. 2024 May;13(13):e2303619
pubmed: 38340040
Biotechnol Adv. 2012 May-Jun;30(3):766-81
pubmed: 22297133
Mol Neurobiol. 2021 Jun;58(6):2812-2823
pubmed: 33507490
Vaccine. 2007 Apr 12;25(15):2907-12
pubmed: 17007970
Nat Rev Drug Discov. 2007 May;6(5):404-14
pubmed: 17473845
Biochem J. 1974 Nov;143(2):445-51
pubmed: 4477953
Annu Rev Immunol. 2003;21:515-46
pubmed: 12500980
Annu Rev Immunol. 1993;11:331-60
pubmed: 8476565
Vet Microbiol. 2012 Oct 12;159(3-4):327-36
pubmed: 22608103
Front Immunol. 2018 Apr 18;9:826
pubmed: 29720983
Vet Microbiol. 2017 Jul;206:10-20
pubmed: 28069290
Am J Vet Res. 2020 Jun;81(6):521-526
pubmed: 32436789
Vet Microbiol. 2003 Nov 7;96(4):367-84
pubmed: 14599784
Clin Vaccine Immunol. 2014 Dec;21(12):1628-34
pubmed: 25274802
Int J Pharm. 2024 Jul 20;660:124320
pubmed: 38866086
Vaccine. 2012 Mar 16;30(13):2336-41
pubmed: 22300723
Biomolecules. 2021 Feb 17;11(2):
pubmed: 33671255
Vaccine. 2001 Oct 12;20(1-2):86-91
pubmed: 11567750
BMC Microbiol. 2020 Feb 4;20(1):26
pubmed: 32019519
Pharm Nanotechnol. 2019;7(3):181-205
pubmed: 31486750